Eczema drug Tralokinumab's eye risks under the microscope
NCT ID NCT05682976
First seen May 10, 2026 · Last updated May 10, 2026
Summary
This study looked at eye problems in 100 adults with atopic dermatitis (eczema) who were treated with tralokinumab. The main goal was to find out how often eye issues like conjunctivitis happen with this medication. Researchers followed participants for 4 months to track any new or worsening eye conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille
Lille, France
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Brest
Brest, France
-
CHU de Clermont Ferrand
Clermont-Ferrand, France
-
CHU de Nantes
Nantes, France
-
CHU de Rouen
Rouen, France
-
CHu de Dijon
Dijon, France
-
CHu de Poitiers
Poitiers, France
-
CHu de Rennes
Rennes, France
-
Hospice Civil de Lyon
Lyon, France
-
Hôpital Saint Louis
Paris, France
Conditions
Explore the condition pages connected to this study.